Bilal Hazrat, Khan Muhammad Nadeen, Khan Sabir, Shafiq Muhammad, Fang Wenjie, Zeng Yuebin, Guo Yangzhong, Li Xiaohui, Zhao Bing, Lv Qiao-Li, Xu Bin
Jiangxi Key Laboratory of Oncology, JXHC Key Laboratory of Tumor Metastasis, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, China.
Department of Cell Biology and Genetics, Shantou University Medical College, Shantou, China.
Cancer Res. 2025 Feb 1;85(3):413-423. doi: 10.1158/0008-5472.CAN-24-1609.
Fungal dysbiosis is increasingly recognized as a key factor in cancer, influencing tumor initiation, progression, and treatment outcomes. This review explores the role of fungi in carcinogenesis, with a focus on mechanisms such as immunomodulation, inflammation induction, tumor microenvironment remodeling, and interkingdom interactions. Fungal metabolites are involved in oncogenesis, and antifungals can interact with anticancer drugs, including eliciting potential adverse effects and influencing immune responses. Furthermore, mycobiota profiles have potential as diagnostic and prognostic biomarkers, emphasizing their clinical relevance. The interplay between fungi and cancer therapies can affect drug resistance, therapeutic efficacy, and risk of invasive fungal infections associated with targeted therapies. Finally, emerging strategies for modulating mycobiota in cancer care are promising approaches to improve patient outcomes.
真菌生态失调日益被认为是癌症的关键因素，影响肿瘤的发生、发展和治疗结果。本综述探讨了真菌在致癌过程中的作用，重点关注免疫调节、炎症诱导、肿瘤微环境重塑和跨界相互作用等机制。真菌代谢产物参与肿瘤发生，抗真菌药物可与抗癌药物相互作用，包括引发潜在不良反应和影响免疫反应。此外，真菌群落谱具有作为诊断和预后生物标志物的潜力，强调了它们的临床相关性。真菌与癌症治疗之间的相互作用可影响耐药性、治疗效果以及与靶向治疗相关的侵袭性真菌感染风险。最后，癌症治疗中调节真菌群落的新兴策略是改善患者预后的有前景的方法。
